# Intra-Cellular Therapies, Inc. – Consensus ‘buy’ rating and 56.4% Upside Potential

- Link: https://www.directorstalkinterviews.com/intra-cellular-therapies-inc.consensus-buy-rating-and-56.4-upside-potential/4121131754
- Published: 2023-11-01T13:44:07+00:00
- Author: Charlotte Edwards

**Intra-Cellular Therapies, Inc.** with ticker code (ITCI) have now 12 analysts 
in total covering the stock. The consensus rating is pointing to ‘buy’. The target
price High/Low ranges between $100.00 and $59.00 suggesting an average Analsyt target
price of $77.83. Now with the previous closing price of $49.76 this indicates there
is a potential upside of 56.4%. The 50 day MA is $53.54 and the 200 moving average
now moves to $56.02. The market capitalization for the company is 4.77B. The stock
price for the company is currently $49.68 USD

 The potential market cap would be $7,466,785,369 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $3.85 and
a -16.27% return on assets.

Intra-Cellular Therapies, Inc. is a biopharmaceutical company. The Company is focused
on the discovery, clinical development and commercialization of small molecule drugs
that address underserved medical needs primarily in neuropsychiatric and neurological
disorders by targeting intracellular signaling mechanisms within the central nervous
system (CNS). The Company’s product CAPLYTA is a treatment for depressive episodes
associated with bipolar I or II disorder (bipolar depression) in adults as monotherapy
and as adjunctive therapy with lithium or valproate. The efficacy of CAPLYTA 42 
mg in bipolar depression was demonstrated in two positive Phase III placebo-controlled
bipolar depression studies, which evaluated the effects of CAPLYTA on depression
in adult patients with bipolar I or bipolar II disorder both as monotherapy (Study
404) and as adjunctive therapy with lithium or valproate (Study 402).

Share on: